Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

Jacques Medioni; Eugeniu Banu; Dominique Helley; Florian Scotte; Laure Fournier; Arnaud Mejean; Antoine Chedid; Michel Azizi; Jean Marie Andrieu; Stéphane Oudard

doi:10.1016/j.eururo.2009.01.001

Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

Jacques Medioni, Eugeniu Banu, Dominique Helley, Florian Scotte, Laure Fournier, Arnaud Mejean, Antoine Chedid, Michel Azizi, Jean Marie Andrieu, Stéphane Oudard

Research output: Contribution to journal › Short survey › peer-review

18 Citations (Scopus)

Abstract

We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile. Crown

Original language	English
Pages (from-to)	207-211
Number of pages	5
Journal	European Urology
Volume	56
Issue number	1
DOIs	https://doi.org/10.1016/j.eururo.2009.01.001
Publication status	Published - 1 Jul 2009
Externally published	Yes

Keywords

Bevacizumab
Renal cell carcinoma
Salvage therapy
Sunitinib

Access to Document

10.1016/j.eururo.2009.01.001

Cite this

@article{33052d4eedba4f508242341505e5cb70,

title = "Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series",

abstract = "We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile. Crown",

keywords = "Bevacizumab, Renal cell carcinoma, Salvage therapy, Sunitinib",

author = "Jacques Medioni and Eugeniu Banu and Dominique Helley and Florian Scotte and Laure Fournier and Arnaud Mejean and Antoine Chedid and Michel Azizi and Andrieu, {Jean Marie} and St{\'e}phane Oudard",

year = "2009",

month = jul,

day = "1",

doi = "10.1016/j.eururo.2009.01.001",

language = "English",

volume = "56",

pages = "207--211",

journal = "European Urology",

issn = "0302-2838",

number = "1",

}

TY - JOUR

T1 - Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma

T2 - A Case Series

AU - Medioni, Jacques

AU - Banu, Eugeniu

AU - Helley, Dominique

AU - Scotte, Florian

AU - Fournier, Laure

AU - Mejean, Arnaud

AU - Chedid, Antoine

AU - Azizi, Michel

AU - Andrieu, Jean Marie

AU - Oudard, Stéphane

PY - 2009/7/1

Y1 - 2009/7/1

N2 - We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile. Crown

AB - We present a case series of seven patients with metastatic renal cell carcinoma treated with bevacizumab (10 mg/kg) in combination with sunitinib 25-50 mg as salvage therapy after disease progression under sunitinib monotherapy. Two patients had a partial response, four had stable disease, and one patient had disease progression. After a median follow-up of 17.2 mo, median progression-free survival and overall survival were 8.5 and 15.1 mo, respectively. Two patients experienced exacerbation of their preexisting hypertension; there were no grade 4 toxicities. The bevacizumab-sunitinib combination in sunitinib-refractory patients seems active and has a tolerable toxicity profile. Crown

KW - Bevacizumab

KW - Renal cell carcinoma

KW - Salvage therapy

KW - Sunitinib

UR - http://www.scopus.com/inward/record.url?scp=67349171021&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2009.01.001

DO - 10.1016/j.eururo.2009.01.001

M3 - Short survey

C2 - 19157688

AN - SCOPUS:67349171021

SN - 0302-2838

VL - 56

SP - 207

EP - 211

JO - European Urology

JF - European Urology

IS - 1

ER -

Salvage Therapy with Bevacizumab-Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

Abstract

Keywords

Access to Document

Other files and links

Cite this